Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modif… Read more
Biomea Fusion Inc (BMEA) - Net Assets
Latest net assets as of September 2025: $15.62 Million USD
Based on the latest financial reports, Biomea Fusion Inc (BMEA) has net assets worth $15.62 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($55.19 Million) and total liabilities ($39.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.62 Million |
| % of Total Assets | 28.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | 897.74% |
| 10-Year Change | N/A |
| Growth Volatility | 1462.75 |
Biomea Fusion Inc - Net Assets Trend (2019–2024)
This chart illustrates how Biomea Fusion Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biomea Fusion Inc (2019–2024)
The table below shows the annual net assets of Biomea Fusion Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $51.57 Million | -69.53% |
| 2023-12-31 | $169.24 Million | +55.92% |
| 2022-12-31 | $108.54 Million | -39.29% |
| 2021-12-31 | $178.78 Million | +3358.75% |
| 2020-12-31 | $5.17 Million | +24714.29% |
| 2019-12-31 | $-21.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biomea Fusion Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38440000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.01% |
| Other Components | $438.82 Million | 850.87% |
| Total Equity | $51.57 Million | 100.00% |
Biomea Fusion Inc Competitors by Market Cap
The table below lists competitors of Biomea Fusion Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Horizon Minerals Ltd
AU:HRZ
|
$80.34 Million |
|
Bursa De Valori Bucuresti SA
RO:BVB
|
$80.39 Million |
|
Visiomed Group SA
PINK:VMDGF
|
$80.39 Million |
|
Coya Therapeutics, Inc. Common Stock
NASDAQ:COYA
|
$80.41 Million |
|
Oxford Bank Corporation
PINK:OXBC
|
$80.28 Million |
|
Genelux Corporation Common Stock
NASDAQ:GNLX
|
$80.28 Million |
|
Licogi 16 JSC
VN:LCG
|
$80.27 Million |
|
Synergy Innovation Co. Ltd
KQ:048870
|
$80.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biomea Fusion Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 169,237,000 to 51,573,000, a change of -117,664,000 (-69.5%).
- Net loss of 138,426,000 reduced equity.
- Other factors increased equity by 20,762,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-138.43 Million | -268.41% |
| Other Changes | $20.76 Million | +40.26% |
| Total Change | $- | -69.53% |
Book Value vs Market Value Analysis
This analysis compares Biomea Fusion Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.85x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.00 | $1.22 | x |
| 2020-12-31 | $0.48 | $1.22 | x |
| 2021-12-31 | $7.49 | $1.22 | x |
| 2022-12-31 | $3.71 | $1.22 | x |
| 2023-12-31 | $4.96 | $1.22 | x |
| 2024-12-31 | $1.43 | $1.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biomea Fusion Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -268.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.55x
- Recent ROE (-268.41%) is below the historical average (-89.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.20 Million |
| 2020 | -103.00% | 0.00% | 0.00x | 12.10x | $-5.84 Million |
| 2021 | -23.05% | 0.00% | 0.00x | 1.04x | $-59.10 Million |
| 2022 | -73.73% | 0.00% | 0.00x | 1.19x | $-90.88 Million |
| 2023 | -69.28% | 0.00% | 0.00x | 1.18x | $-134.18 Million |
| 2024 | -268.41% | 0.00% | 0.00x | 1.55x | $-143.58 Million |
Industry Comparison
This section compares Biomea Fusion Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biomea Fusion Inc (BMEA) | $15.62 Million | 0.00% | 2.53x | $80.34 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |